PANCREATICODUODENECTOMY (PD) is a multiorgan operative procedure with a high incidence of morbidity 1-3 among patients with periampullary disease. Postoperative paralytic ileus after abdominal surgery is a common/uncomfortable complication and is recognized as an inevitable response to intraperitoneal surgery. [4] [5] [6] Recently, several studies have reported that a fast-track recovery program decreases the incidence of morbidity and the duration of the postoperative hospital stay among patients undergoing PD. 7 The systemic rehabilitation can increase the intra-abdominal pressure, which would promote bowel peristalsis and the passage of flatus. Maintenance of bowel motility is essential for favorable fast-track recovery from postoperative paralytic ileus. The evidence for paralytic ileus depends on the observations that abdominal distention occurs often in the immediate postoperative period, bowel sounds are not heard, and passage of flatus or stool is delayed for several days. 8 A past study chose to use to examine as parameters the relationship of bowel sounds and the time to first flatus as gastrointestinal function. 9 Daikenchuto (TJ-100), a traditional Japanese herbal medicine, has been used widely for the prevention and treatment of postoperative ileus. [10] [11] [12] [13] TJ-100 extract powder is manufactured by Tsumura & Co. (Tokyo, Japan) as an aqueous extract containing 2.2% Japanese pepper, 5.6% processed ginger, 3.3% ginseng, and 88.9% maltose syrup powder. Previous pharmacologic studies suggest that acetylcholine released from intrinsic cholinergic nerves and tachykinins from sensory neurons are involved in the contractions induced by sansyo (hydroxy b-sanshool), which is the main ingredient of TJ-100. 14 Tsumura & Co. submitted an IND (Investigational New Drug Application) of TJ-100 to the U.S. Food and Drug Administration (FDA). The drug has been approved by the FDA as an investigational drug, and many placebocontrolled double-blinded trials have been launched in the United States to investigate its use for postoperative ileus (NCT02232893, NCT00266461, NCT00871325), constipation (NCT01139216, NCT01348152), irritable bowel syndrome (NCT01890837, NCT02074579), and Crohn disease (NCT01388933). 15 Despite the widespread and common use of TJ-100 in Japanese clinical practice, its impact on the normalization of bowel peristalsis after PD remains unclear in the prospective study, and whether this traditional Japanese herbal medicine actually makes a difference in postoperative paralytic ileus in the setting of modern perioperative management remains controversial. The results of our previous prospective cohort study (UMIN-CTR ID no. 000005056) indicated that perioperative administration of TJ-100 decreases paralytic ileus substantially after PD and that the time to first postoperative flatus occurs substantially earlier in patients who receive perioperative TJ-100 14 ; however, the previous study was neither placebocontrolled nor randomized/blinded, and there is a limitation because of the small number of cases. To confirm the results of the cohort study, we conducted a multicenter, randomized, placebocontrolled phase II trial (JAPAN-PD Study) of TJ-100 to evaluate whether perioperative administration of TJ-100 reduces the incidence of postoperative paralytic ileus after PD.
PATIENTS AND METHODS
Study oversight and author contributions. The JAPAN-PD study is a multicenter, randomized, double-blinded, placebo-controlled, phase II trial conducted at 9 high-volume centers for pancreatic surgery certified by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. The trial was approved by the institutional review board of each participating institution. This trial is registered at the UMIN Clinical Trials Registry (no. 000007975) and at ClinicalTrials.gov (no. NCT01607307). An independent data and safety monitoring board provided regulatory oversight by reviewing concealed patient data annually. The data and safety monitoring board also conducted a prespecified interim analysis after the enrollment of 224 patients who had been confirmed to be eligible for the study. The study was designed and initiated by the academic investigators and was funded by the Epidemiological and Clinical Research Information Network. Employees of Tsumura & Co. did not have access to the data during the trial, did not participate in the data analysis, and did not participate in the preparation of the manuscript.
Patients. Eligible patients enrolled in this study were adults ($20 years of age) who were scheduled to undergo PD for periampullary tumors and tumors of the head of the pancreas. 16 The following types of patients were excluded: patients with tumors that required resection of the colon; patients who were expected to have severe intraabdominal adhesions as the result of previous surgery or peritonitis; patients who had used gastrointestinal prokinetic medication, antipsychotic medication, or antidepressants; and patients who had used Japanese herbal (Kampo) medicines within 4 weeks before registration. 16 Accelerated perioperative rehabilitation was used in all the participating 9 centers.
Randomization and study protocol. Randomization was carried out according to the previously published protocol paper. 16 The type of primary disease, the presence of neoadjuvant therapy, the presence of the pylorus ring of the remnant stomach, and the presence of the postoperative enteral alimentation were determined as balancing subgroups. Patients were enrolled ultimately from 9 high-volume centers that submitted case report forms without any protocol violation. After providing written informed consent, patients were assigned randomly in a 1:1 ratio to receive TJ-100 or placebo. A solution of 5 g of TJ-100 or placebo was administered orally 3 times daily (15 g/day) immediately before meals or every 8 hours for 17 consecutive days (from preoperative day 3 to postoperative day 14), except on the operative day and on postoperative day 1; on the operative day, TJ-100 or placebo was administered immediately after the operation in a single 5-g dose as a diluent via a delivering tube (10 Fr) inserted into jejunum; and on postoperative day 1, 3 doses of 5 g were delivered via a delivering tube to prevent aspiration pneumonia. 16 We prohibited the combination use with gastrointestinal prokinetic medication, antipsychotic medication, or antidepressants by the protocol of this study. Seprafilm Adhesion Barrier Genzyme Corporation, Cambridge, MA and epidural analgesia were used at the discretion of each institution. 17, 18 Primary and secondary endpoints. In this clinical trial, the coprimary endpoints were (1) incidence of postoperative paralytic ileus lasting >72 hours after surgery and (2) time to occurrence of postoperative paralytic ileus. Postoperative paralytic ileus was defined as delay of the first postoperative flatus lasting for >72 hours (3.0 days) after surgery based on the description about the definition of paralytic ileus in the previous literature, 4, 5 or some other status requiring intervention for treatment for ileus; 12 hours was counted as 0.5 postoperative day, and 24 hours as 1.0 postoperative day. The secondary endpoints were the incidence of postoperative paralytic ileus in cases which combined with/without enteral alimentation, quality of life (QOL) assessment by the Gastrointestinal Symptom Rating Scale Score (Japanese version), assessment of abdominal pain and abdominal distention by means of a visual analog scale, the ratio of the abdominal circumference on postoperative day 3 to the circumference on the operative day immediately after surgery, the incidence of postoperative complications, the duration of the postoperative hospital stay, the incidence of surgical-site infection, and the incidence of postoperative small bowel obstruction within 2 years after surgery.
Adverse events and dose modifications. Toxicities and adverse events were evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.0. The criteria for dose reduction and discontinuation of the protocol treatment were as follows. In cases in which grade 2 postoperative diarrhea or other clinical adverse event was observed, the dose of the TJ-100 or the placebo was reduced to 2.5 g, and in case of grade 3 postoperative diarrhea or other clinical adverse event was observed, the protocol treatment was terminated. 16 Drain placement and drainage fluid collection. Drains were placed surgically into the foramen of Winslow and intraperitoneal space around the pancreaticoenterostomy in all of the patients who received TJ-100 and placebo according to the study protocol. The drainage fluid was collected and examined for amylase level on postoperative day 1, 3, and 4 to evaluate pancreatic fistula.
Measurement of serum and drainage cytokine concentrations. Serum and drainage were obtained on postoperative days 1 and 3 for a multiple cytokine assay. The 27 measured cytokines, the methods of measurement, and the sensitivity level for each cytokines were similar to those previously reported. 14 Complications. All morbidities, the global morbidity rate, and the type of complications were evaluated by means of the classification of Dindo. 19 Postoperative delayed gastric emptying (DGE), postoperative pancreatic fistula, and intraabdominal hemorrhage were interpreted to the classification of Dindo based on the consensus definition and the clinical grading of DGE proposed by the International Study Group of Pancreatic Surgery, 20 the International Study Group of Pancreatic Fistula guidelines, 21 and the International Study Group of Pancreatic Surgery definition of intraabdominal hemorrhage. 22 Surgical-site infections included surgical wound or intra-abdominal abscesses with positive cultures. Mortality was defined as all deaths related to surgery.
Statistical analysis. Sample-size calculation and statistical considerations were predefined in the protocol paper 16 of this study previously published in The Japanese Journal of Clinical Oncology as follows: the multiplicity issue (inflation of the type I error) as the result of analyzing 2 endpoints was addressed with the Bonferroni method. That is, the significance levels for both tests are set at 2.5% to control the overall type I error rate. The sample size was calculated on the basis that the incidence rate of postoperative paralytic ileus for 72 hours after surgery was expected to be 90% for the placebo group. The expected value of 90% for the placebo group was expected on the basis of the result of the control group in our previous study. 14 In the event the effect of decreasing the incidence of postoperative paralytic ileus is assumed to be 20% for the TJ-100 group, the least number of patients to provide the 85% power necessary to confirm the superiority of a group was calculated to be 94 per group for a 2-sided 2.5% significance level test. Furthermore, given the number of patients, an 84% statistical power was retained to prove the superiority in terms of time to occurrence of postoperative paralytic ileus for the hazard ratio of 0.62. The significance level for this inference also was set at 2.5%. Taking an exclusion from analysis of approximately 15% into account, we set the number of patients to be accrued at 110 per treatment arm (220 in total). A heterogeneous subgroup of patients were adjusted by central randomization to either Arm A (TJ-100) or Arm B (placebo) by the use of primary disease, implementation of any kind of preoperative therapy, preservation of pylorus ring in the remnant stomach, the presence of enteral alimentation, and the institution as dynamic balancing variables.
Statistical comparisons between 2 groups were made by means of the chi-square statistic, the Fisher exact test, or the Mann-Whitney U test, where appropriate. The risk factors for paralytic ileus were explored by means of a univariate logistic regressions model and a multivariate logistic regression model by use of the stepwise selection method (criteria for variable entry and stay into the model were P = .2 and P = .3, respectively). Odds ratios (ORs) and their 95% confidence intervals (CIs) were used to express the contributions of factors. Statistical significance was defined as P< .05. Median time to first flatus was estimated with Kaplan-Meier method. Group differences were assessed by log-rank test. Relative risk was estimated with the Cox proportional hazards model, and the relative risk smaller than 1 favored TJ-100. With respect to the primary endpoints, the significant levels were 0.025 for each primary endpoint, because this study set two primary endpoints. All the analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Patient characteristics. From August 2012 through July 2013, 273 patients were assessed for eligibility. Of those, 41 cases were excluded by the exclusion criteria, 4 cases were claimed to be ineligible, and 4 patients declined to participate, leaving 224 patients who were assigned randomly to the TJ-100 group (112 patients) or the placebo group (112 patients). In the TJ-100 group, 3 patients (2.7%) did not meet the criteria to take the test medications according to the protocol; 1 patient (0.9%) withdrew consent; and 4 patients (Table I) . No patients underwent PD with artery combined resection in this study.
Baseline compliance with completion of Gastrointestinal Symptom Rating Scale questionnaires was high: in the TJ-100 group, 102 preoperative questionnaires (98.1%) and 100 postoperative questionnaires (96.2%) were completed, and in the placebo group, the corresponding values were Except for age distribution, the preoperative and operative characteristics of the patients were similar in the 2 groups (Table I ). The criteria for dose reduction and discontinuation of the protocol treatment were met by 35 patients (33.7%) in the TJ-100 group and 30 patients (29.1%) in the placebo group (P = .483). These patients, who experienced grade 2 or 3 postoperative diarrhea or other clinical adverse events (CTCAE ver. 4.0 criteria), were administered a decreased dose of the test drug or the placebo (2.5 g) or were immediately discontinued the treatment in accordance with the treatment protocol.
Study outcomes. The coprimary endpoint, ie, postoperative paralytic ileus was met in 73 (32.6%) of the 224 randomized patients (Table II) BMI, Body mass index; C-P-G, reconstruction with jejunum from choledochus, pancreas, to stomach in order; G-C-P, reconstruction with jejunum from stomach, choledochus, to pancreas in order; G-P-C, reconstruction with jejunum from stomach, pancreas, to choledochus in order; P-C-G, reconstruction with jejunum from pancreas, choledochus, to stomach in order; SMA, superior mesenteric artery. received other medications to rescue the condition of severe paralytic ileus after the judge point of 72 hours postoperatively, there were no differences between the 2 groups with regard to the incidence of additional therapy for paralytic ileus, including insertion of a tube into the stomach or jejunum or administration of other drugs to improve bowel motility (Table II) . With regard to the incidence of paralytic ileus, a comparison between the TJ-100 and placebo groups revealed similar findings for the following prespecified subgroups: with or without neoadjuvant therapy, a pylorus ring-preserving PD (PPPD) versus a pylorus-resecting PD, and pancreatic carcinoma versus other types of primary disease.
There also were no substantial differences in time to first flatus among the following subgroups: with or without neoadjuvant therapy, a PPPD versus a pylorus-resecting PD, and pancreatic carcinoma versus other types of primary disease. In contrast, among the 23 patients who underwent PPPD, the time to first flatus was substantially less in the TJ-100 group than in the placebo group: 0.50 (0.50-1.00) days versus1.50 (0.50-3.00) days, respectively (relative risk, 0.46; 95% CI, 0.19-1.13; P = .034). Otherwise, no differences were demonstrated in the other subgroups on the basis of age, sex, presence/absence of Grade B or C pancreatic fistula, and institution.
Postoperative complications. Table III shows the postoperative complications in patients in the TJ-100 and placebo groups. The incidence of postoperative complications revealed no substantial differences between the 2 groups. One patient in the placebo group died from acute respiratory distress syndrome on postoperative day 50; in the TJ-100 group, there were no deaths or reoperations related to surgery.
Adverse events. The overall postoperative mortality was 0.5% (1 death in the placebo group). The overall rate of grade 3 and 4 events (CTCAE ver. 4.0 criteria) at 60 days was 9.7%: 12 patients (11.5%) in the TJ-100 group and 8 patients (7.8%) in the placebo group had grade 3 or 4 adverse events. The majority of these adverse events represented expected diarrhea or postoperative abnormalities in the results of serum chemical analyses. QOL assessment and physical examination. There was no substantial difference between the 2 groups with regard to QOL as assessed by the Gastrointestinal Symptom Rating Scale Score: acid reflux (P = .690), abdominal pain (P = .818), indigestion (P = .900), diarrhea (P = .336), constipation (P = .495), and the sum of all the categories (P = .652). There were also no differences with regard to visual analog scale assessment of abdominal pain (P = .296) and abdominal distention (P = .969) or with regard to the ratio of abdominal circumference on postoperative day 3 to that on the operative day just after surgery (P = .320).
Risk factors for paralytic ileus. In univariate analyses, the following factors showed moderate association with paralytic ileus: epidural anesthesia, operative time, blood loss, PPPD, the use of a hyaluronic acid-carboxymethylcellulose membrane (Seprafilm) for adhesion prevention, and dissection of nerve plexus around the superior mesenteric artery. Multivariate analysis revealed that the epidural anesthesia (OR, 2.35; 95% CI, 1.20-4.59; P = .012) and use of Seprafilm (OR, 2.61; 95% CI, 1.27-5.36; P = .009) were independent risk factors for paralytic ileus even after we controlled for the other variables (Table IV) .
Cytokine concentrations in drainage and serum. The 2 groups showed no differences in the concentrations of 27 cytokines in the drainage and serum (data not shown).
DISCUSSION
The results of this multicenter, double-blind, randomized, placebo-controlled trial showed that perioperative treatment with TJ-100 neither decreased the incidence of clinically relevant postoperative paralytic ileus nor shortened the time to first postoperative flatus. TJ-100 does not seem as relevant for surgeons in Western countries, including the United States, whereas it is used commonly in Asian countries. TJ-100, however, is now under clinical development in the United States as a drug to improve postoperative paralysis and QOL after hospital discharge, as commonly accepted in Japan. In United States, 4 clinical pharmacology studies and 2 early phase II studies have been completed. At present, a study to verify the efficacy against abdominal complaints accompanying irritable bowel syndrome and a study to demonstrate recovery of intestinal functions and early improvement of abdominal symptoms after laparoscopic colectomy are ongoing. When these clinical studies have been finished, it is expected that TJ-100 will be approved as a prescription drug by the FDA in the near future, and it will be expected that the American doctors in the gastroenterological surgery field will use this drug in the clinical practice.
This compound apparently is used often in Asia-Pacific countries but has not been incorporated into practice in Western countries. Previous trials investigating the effect of TJ-100 after total gastrectomy, however, demonstrated that TJ-100 greatly shortens the time to first bowel movement. Therefore, the impact of this compound might spread in Western countries. 10, 15 In the present study, among the small subgroup of patients who underwent PPPD, the first flatus was detected 24 hours earlier in the TJ-100 group than in the placebo group. The pylorus-resecting PD is the most commonly used procedure in Japan, because denervation and devascularization of the pylorus ring lead to DGE. 23 Globally, however, PPPD is performed in more than 70% of cases reported in the literature. 24 We could not conclude whether TJ-100 decreases the incidence of the paralytic ileus after PPPD in this study because of the small sample size of the subgroup patients. Otherwise, the lack of significant effects in our study may have been an artifact because of the use of a modern fast-track program, including an accelerated perioperative rehabilitation, 7 to the placebo effect, to tachyphylaxis, to the use of several recent innovations in PD designed to prevent DGE, 23, 25 to the hospital volume, 26 or it may have been a true effect. Therefore, the results in this study may be different from those in our previous study, in which time to first flatus was significantly lower in the TJ-100 group than in the control group: 2.6 days versus 4.7 days. 14 That is, advances in the surgery itself and modern fast track program may have shortened the time to first flatus after PD.
The JAPAN-PD Study was a high-quality trial in which all the participating institutions were highvolume centers of pancreatic surgery certified by the Japanese Society of Hepato-Biliary-Pancreatic Surgery, and 224 patients were randomized in almost 10 months. The trial setting matches the widespread use in recommendation in perioperative clinical practice. Several features of the trial decreased the risk of bias, including central randomization, allocation concealment, masking, and very low attrition. The risk of bias was reduced further by pre-publication of the statistical analysis plan. 16 Our analyses also demonstrated that epidural anesthesia was an independent risk factor for paralytic ileus in patients who underwent PD. 18 Pratt et al. reported that epidural analgesia could not necessarily improve gastrointestinal recovery after PD as the result of inadequate analgesia, although a recent meta-analysis of randomized controlled trials reported that epidural analgesia improves recovery of bowel function. 18, 27 Seprafilm has been reported to be associated with an increased risk of abdominal abscess or sterile inflammation, 17, 28 but the incidence of intraperitoneal abscess in our series was low, considering the Seprafilm insertion rates (Tables I and III) . Therefore, we could not identify the reasons why or mechanisms of how these factors induced paralytic ileus in the setting of the present study.
Our findings suggest that the use of TJ-100 does not improve recovery from paralytic ileus, QOL, abdominal circumference after PD compared with placebo, and may preclude the routine use of TJ-100 in the clinical practice after PD operations.
